Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure
Go back to Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure| (NASDAQ: CRDL) | Delayed: 1.41 -0.15 (9.62%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.56 | 52 Week High | $ | |||
| Open | $1.60 | 52 Week Low | $ | |||
| Day High | $1.64 | P/E | N/A | |||
| Day Low | $1.40 | EPS | $ | |||
| Volume | 3,593,406 | |||||
